AVADEL PHARMACEUTICALS PLC Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2011 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Avadel Pharmaceuticals Plc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2011 to Q2 2024.
  • Avadel Pharmaceuticals Plc Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$13.8M, a 78.5% increase year-over-year.
  • Avadel Pharmaceuticals Plc Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$106M, a 25.6% increase year-over-year.
  • Avadel Pharmaceuticals Plc annual Net Income (Loss) Attributable to Parent for 2023 was -$160M, a 16.6% decline from 2022.
  • Avadel Pharmaceuticals Plc annual Net Income (Loss) Attributable to Parent for 2022 was -$137M, a 77.8% decline from 2021.
  • Avadel Pharmaceuticals Plc annual Net Income (Loss) Attributable to Parent for 2021 was -$77.3M, a 1200% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$106M -$13.8M +$50.6M +78.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$157M -$27.3M +$3.44M +11.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-08
Q4 2023 -$160M -$28.8M -$1.34M -4.87% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 -$159M -$36.3M -$16.1M -80.1% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 -$143M -$64.4M -$988K -1.56% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$142M -$30.8M -$4.36M -16.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-08
Q4 2022 -$137M -$27.5M -$5.15M -23.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 -$132M -$20.1M +$1.86M +8.44% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$134M -$63.4M -$43.9M -224% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-08
Q1 2022 -$90.3M -$26.4M -$13M -96.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-08
Q4 2021 -$77.3M -$22.3M -$11M -97.7% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 -$66.3M -$22M -$10.3M -88% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$56M -$19.6M -$50.5M -163% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 -$5.55M -$13.4M -$12.6M -1454% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 $7.03M -$11.3M -$8.54M -312% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-16
Q3 2020 $15.6M -$11.7M -$2.84M -32% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $18.4M $30.9M +$39.5M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-08
Q1 2020 -$21.1M -$865K +$12.2M +93.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-08
Q4 2019 -$33.2M -$2.74M +$61.1M +95.7% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-16
Q3 2019 -$94.3M -$8.86M +$6.91M +43.8% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$101M -$8.61M -$5.17M -150% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-09
Q1 2019 -$96.1M -$13M -$782K -6.39% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-09
Q4 2018 -$95.3M -$63.9M -$55.6M -675% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-09
Q3 2018 -$39.7M -$15.8M -$37.5M -173% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$2.24M -$3.44M -$32.4M -112% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-12
Q1 2018 $30.1M -$12.2M -$38.1M -147% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-12
Q4 2017 $68.3M -$8.25M -$13M -274% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-16
Q3 2017 $81.3M $21.7M +$41.7M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-05
Q2 2017 $39.6M $28.9M +$48.9M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 -$9.31M $25.9M +$32M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-04
Q4 2016 -$41.3M $4.73M -$70.4M -93.7% Oct 1, 2016 Dec 31, 2016 10-K 2019-03-15
Q3 2016 $29.1M -$20M +$8.08M +28.8% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 $21M -$20M -$3.1M -18.4% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $24.1M -$6.06M -$17.7M -152% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q4 2015 $41.8M $75.1M +$103M Oct 1, 2015 Dec 31, 2015 10-K 2018-03-16
Q3 2015 -$61M -$28.1M -$18M -179% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-14
Q2 2015 -$43M -$16.9M +$4.22M +20% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-15
Q1 2015 -$47.2M $11.6M +$38.3M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q4 2014 -$85.5M -$27.7M -$32.8M -641% Oct 1, 2014 Dec 31, 2014 10-K 2017-03-28
Q3 2014 -$52.6M -$10M -$3.68M -57.7% Jul 1, 2014 Sep 30, 2014 6-K 2014-11-17
Q2 2014 -$49M -$21.1M +$11.8M +35.9% Apr 1, 2014 Jun 30, 2014 6-K 2015-12-31
Q1 2014 -$60.7M -$26.6M -$17.8M -202% Jan 1, 2014 Mar 31, 2014 6-K 2015-07-10
Q4 2013 -$42.9M $5.13M -$3.98M -43.7% Oct 1, 2013 Dec 31, 2013 10-K 2016-03-15
Q3 2013 -$39M -$6.37M +$56K +0.87% Jul 1, 2013 Sep 30, 2013 6-K 2014-11-17
Q2 2013 -$39M -$32.9M -$26.9M -455% Apr 1, 2013 Jun 30, 2013 6-K 2014-08-08
Q1 2013 -$12.1M -$8.83M -$8.84M Jan 1, 2013 Mar 31, 2013 6-K 2014-07-08
Q4 2012 -$3.23M $9.1M Oct 1, 2012 Dec 31, 2012 20-F/A 2015-10-01
Q3 2012 -$6.43M Jul 1, 2012 Sep 30, 2012 6-K 2014-01-15
Q2 2012 -$5.92M -$2.46M -71.1% Apr 1, 2012 Jun 30, 2012 6-K 2013-12-06
Q1 2012 $12K* +$4.94M Jan 1, 2012 Mar 31, 2012 6-K 2012-09-13
Q2 2011 -$3.46M Apr 1, 2011 Jun 30, 2011 6-K 2012-12-14
Q1 2011 -$4.93M Jan 1, 2011 Mar 31, 2011 6-K 2012-09-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.